{"id":"buspirone-pap-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Lightheadedness"},{"rate":null,"effect":"PAP mask discomfort or skin irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buspirone selectively binds to and activates 5-HT1A receptors in the brain, reducing anxiety symptoms without the sedation or dependence associated with benzodiazepines. PAP therapy delivers pressurized air through a mask to prevent airway collapse during sleep, restoring normal breathing patterns and oxygen saturation. This combination addresses both anxiety and sleep-disordered breathing, which often co-occur.","oneSentence":"Buspirone acts as a serotonin 5-HT1A receptor agonist to reduce anxiety, while PAP (positive airway pressure) therapy mechanically maintains airway patency during sleep to treat obstructive sleep apnea.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:29:11.941Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Generalized anxiety disorder with comorbid obstructive sleep apnea"}]},"trialDetails":[{"nctId":"NCT04118387","phase":"PHASE4","title":"Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-01-07","conditions":"Sleep Disordered Breathing, Able Bodied","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Buspirone + PAP therapy","genericName":"Buspirone + PAP therapy","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buspirone acts as a serotonin 5-HT1A receptor agonist to reduce anxiety, while PAP (positive airway pressure) therapy mechanically maintains airway patency during sleep to treat obstructive sleep apnea. Used for Generalized anxiety disorder with comorbid obstructive sleep apnea.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}